Related Experiment Video
Updated: Mar 19, 2026

Author Spotlight: Generation and Manipulation of Rat Intestinal Organoids
Published on: June 23, 2023
A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice
Megan Vitko1, Dana M Valerio2, Philip D Rye3
1Department of Genetics and Genome Sciences, Case Western Reserve University, United States.
Background:
Cystic fibrosis (CF) patients experience intestinal complications characterized by the accumulation of thick viscous mucus. CF mice were utilized to determine if a novel guluronate oligomer, OligoG, may be a potential therapy in reducing intestinal mucus and subsequent CF-related intestinal manifestations.
Methods:
Intestinal transit, intestinal histology, survival and growth were examined in wildtype and CF mice on regular water and OligoG.
Conclusions:
OligoG improves intestinal transit and survival in CF mice by reducing the accumulation of intestinal mucus. OligoG's ability to directly bind mucin, disrupt mucin interaction and/or sequester calcium allowing for mucin expansion may explain the decrease in mucus accumulation.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

